Ferumoxytol for Magnetic Resonance Imaging in Patients With Severe Kidney Disease
Status:
Enrolling by invitation
Trial end date:
2023-02-27
Target enrollment:
Participant gender:
Summary
There are no current alternatives to diagnostic contrast-requiring imaging for patients with
an eGFR <30mL/min due to the association of gadolinium-based imaging modalities to
nephrogenic systemic fibrosis and iodinated contrast-induced kidney injury.
Ferumoxytol-enhanced imaging may offer an alternative approach.